Skip to main content
SpringerLink
Log in

Cancer Chemotherapy in Older Adults

A Tolerability Perspective

  • Review Article
  • Adverse Effects
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Summary

The incidence of cancer increases with age. Since the geriatric population is growing, we will be confronted with an increasing number of patients with cancer who are >65 years of age. The purpose of this review is to address the use of cancer chemotherapy in older persons with respect to its tolerability.

We performed a review of the literature using ‘Medline’ and the bibliographies of pertinent publications. Information about cancer treatment in older adults was extracted with particular attention to chemotherapy-related toxicity in patients aged >65 years. Comorbid disease, polypharmacy/drug interactions, psychosocial issues and age-related physiological changes are major issues in caring for older patients with cancer. Since older individuals may have a greater number of comorbid illnesses, treatment should be initiated on the basis of physiological rather than chronological age.

Comparative studies show that chemotherapy-related toxicity is similar in older and younger patients, with the exception of haematological toxicity, which may be more severe in older patients, and cardiotoxicity, which is more frequent in the elderly. Other evidence suggests that gastrointestinal and neurotoxicities may also be more severe in older individuals. The dosages of chemotherapeutic agents that are primarily renally excreted may require adjustment in older patients. Haematological reserve is decreased in older individuals, and drugs that cause myelosuppression must be used with care. The use of haemopoietic growth factors in geriatric patients is currently being investigated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Samet J, Hunt WC, Key C, et al. Choice of cancer therapy varies with age of patient. JAMA 1986; 255: 3385–90

    Article  PubMed  CAS  Google Scholar 

  2. Fentiman IS. Treatment of cancer in the elderly [editorial]. Br J Cancer 1991; 64: 993–5

    Article  PubMed  CAS  Google Scholar 

  3. Fentiman IS, Tirelli U, Monfardini S, et al. Cancer in the elderly: why so badly treated? Lancet 1990; 335: 1020–2

    Article  PubMed  CAS  Google Scholar 

  4. Mor V, Masterson-Allen S, Goldberg RJ, et al. Relationship between age at diagnosis and treatments received by cancer patients. J Am Geriatr Soc 1985; 33: 585–9

    PubMed  CAS  Google Scholar 

  5. Begg CB, Carbone PP. Clinical trials and drug toxicity in the elderly: the experience of the Eastern Cooperative Oncology Group. Cancer 1983; 52: 1986–92

    Article  PubMed  CAS  Google Scholar 

  6. Begg CB, Cohen JL, Ellerton J. Are the elderly predisposed to toxicity from cancer chemotherapy? An investigation using data from the Eastern Cooperative Oncology Group. Cancer Clin Trials 1980; 3: 369–74

    PubMed  CAS  Google Scholar 

  7. Christman K, Muss HB, Case LD, et al. Chemotherapy of metastatic breast cancer in the elderly: the Piedmont Oncology Association experience. JAMA 1992; 268: 57–62

    Article  PubMed  CAS  Google Scholar 

  8. Lamy PP. Modifying drug dosage in elderly patients. In: Covington TR, Walker JI, editors. Current geriatric therapy. Philadelphia: W.B. Saunders Company, 1984: 35–72

    Google Scholar 

  9. Satariano WA, Ragland DR. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med 1994; 120: 104–10

    PubMed  CAS  Google Scholar 

  10. Shaw PG. Common pitfalls in geriatric drug prescribing. Drugs 1982; 23: 324–8

    Article  PubMed  CAS  Google Scholar 

  11. Greenblatt DJ, Sellers EM, Shader RI. Drug therapy: drug disposition in old age. N Engl J Med 1982; 306: 1081–8

    Article  PubMed  CAS  Google Scholar 

  12. Beers MH, Ouslander JG. Risk factors in geriatric drug prescribing: a practical guide to avoiding problems. Drugs 1989; 37: 105–12

    Article  PubMed  CAS  Google Scholar 

  13. Ganz PA. Age and gender as factors in cancer therapy. Clin Geriatr Med 1993; 9: 145–55

    PubMed  CAS  Google Scholar 

  14. Ross CE, Mirowsky J. Socially-desirable response and acquiescence in a cross-cultural survey of mental health. J Health Soc Behav 1984; 25: 189–97

    Article  PubMed  CAS  Google Scholar 

  15. Newcomb PA, Carbone PP. Cancer treatment and age: patient perspectives. J Natl Cancer Inst 1993; 85: 1580–4

    Article  PubMed  CAS  Google Scholar 

  16. Nerenz DR, Love RR, Leventhal H, et al. Psychosocial consequences of cancer chemotherapy for elderly patients. Health Serv Res 1986; 20: 961–76

    PubMed  CAS  Google Scholar 

  17. Lichtman SM. Physiological aspects of aging: implications for the treatment of cancer. Drugs Aging 1995; 7: 212–25

    Article  PubMed  CAS  Google Scholar 

  18. Hartsock RJ, Smith EB, Petty CS. Normal variations with aging of the amount of hematopoietic tissue in bone marrow from the anterior iliac crest: a study made from 177 cases of sudden death examined by necropsy. Am J Clin Pathol 1965; 43: 326–31

    PubMed  CAS  Google Scholar 

  19. Robert J, Hoerni B. Age dependence of the early-phase pharmacokinetics of doxorubicin. Cancer Res 1983; 43: 4467–9

    PubMed  CAS  Google Scholar 

  20. McLachlan MS. The ageing kidney. Lancet 1978; II: 143–5

    Article  Google Scholar 

  21. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31–42

    Article  PubMed  CAS  Google Scholar 

  22. Chabner B. Clinical strategies for cancer treatment: the role of drugs. In: Chabner B, Collins J, editors. Cancer chemotherapy: principles and practice. Philadelphia: J.B. Lippincott, 1990: 1–15

    Google Scholar 

  23. Lipschitz DA, Udupa KB. Age and the hematopoietic system. J Am Geriatr Soc 1986; 34: 448–54

    PubMed  CAS  Google Scholar 

  24. Baime MJ, Nelson JB, Castell DO. Aging of the gastrointestinal system. In: Hazzard WR, Bierman EL, Blass JP, et al., editors. Principles of geriatric medicine and gerontology. 3rd ed. New York: McGraw-Hill, 1994: 665–81

    Google Scholar 

  25. Bender AD. The effect of increasing age on the distribution of peripheral blood flow in man. J Am Geriatr Soc 1965; 13: 192–8

    PubMed  CAS  Google Scholar 

  26. Montamat SC, Cusack BJ, Vestal RE. Management of drug therapy in the elderly. N Engl J Med 1989; 321: 303–9

    Article  PubMed  CAS  Google Scholar 

  27. Geokas MC, Lakatta EG, Makinodan T, et al. The aging process. Ann Intern Med 1990; 113: 455–66

    PubMed  CAS  Google Scholar 

  28. Maloney AG, Schumucker DL, Vessey DS. The effects of aging on the hepatic microsomal mixed-function oxidase system of male and female monkeys. Hepatology 1986; 6: 282–7

    Article  PubMed  CAS  Google Scholar 

  29. Powis G. Effect of human renal and hepatic disease on the pharmacokinetics of anticancer drugs. Cancer Treat Rev 1982; 9: 85–124

    Article  PubMed  CAS  Google Scholar 

  30. Terry LC, Halter JB. Aging of the endocrine system. In: Hazzard WR, Bierman EL, Blass JP, et al., editors. Principles of geriatric medicine and gerontology. 3rd ed. New York: McGraw-Hill, 1994: 791–806

    Google Scholar 

  31. Rowe JW, Andres R, Tobin JD, et al. The effect of age on creatinine clearance in men: a cross-sectional and longitudinal study. J Gerontol 1976; 31: 155–63

    PubMed  CAS  Google Scholar 

  32. Rothstein G. Hematopoiesis in the aged: a model of hematopoietic dysregulation? Blood 1993; 82: 2601–4

    PubMed  CAS  Google Scholar 

  33. Mayersohn M. Special pharmacokinetic considerations in the elderly. In: Evans WE, editor. Applied pharmacokinetics: principles of therapeutic drug monitoring. 2nd ed. Vancouver: Applied Therapeutics, 1986: 244–6

    Google Scholar 

  34. Evans MA, Triggs EJ, Cheung M, et al. Gastric emptying rate in the elderly: implications for drug therapy. J Am Geriatr Soc 1981; 29: 201–5

    PubMed  CAS  Google Scholar 

  35. Moore JG, Tweedy C, Christian PE, et al. Effect of age on gastric emptying of liquid-solid meals in man. Dig Dis Sci 1983; 28: 340–4

    Article  PubMed  CAS  Google Scholar 

  36. Popper H. Aging and the liver. Prog Liver Dis 1986; 8: 659–83

    PubMed  CAS  Google Scholar 

  37. Woodhouse KW, Wynne HA. Age-related changes in liver size and hepatic blood flow: the influence on drug metabolism in the elderly. Clin Pharmacokinet 1988; 15: 287–94

    Article  PubMed  CAS  Google Scholar 

  38. Balducci L, Mowrey K, Parker M. Pharmacology of antineoplastic agents in older patients. In: Balducci L, Lyman GH, Ershler WB, editors. Geriatric oncology. Philadelphia: J.B. Lippincott, 1992: 169–80

    Google Scholar 

  39. Balducci L, Parker M, Sexton W, et al. Pharmacology of antineoplastic agents in the elderly patient. Semin Oncol 1989; 16: 76–84

    PubMed  CAS  Google Scholar 

  40. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91: 710–7

    Google Scholar 

  41. Poirier J, Finch CE. Neurochemistry of the aging human brain. In: Hazzard WR, Bierman EL, Blass JP, et al., editors. Principles of geriatric medicine and gerontology. 3rd ed. New York: McGraw-Hill, 1994: 1005–12

    Google Scholar 

  42. Brandstetter RD, Kazemi H. Aging and the respiratory system. Med Clin North Am 1983; 67: 419–31

    PubMed  CAS  Google Scholar 

  43. Greenblatt DJ. Reduced serum albumin concentration in the elderly: a report from the Boston Collaborative Drug Surveillance Program. J Am Geriatr Soc 1979; 27: 20–2

    PubMed  CAS  Google Scholar 

  44. Borkowski JM, Duerr M, Donehower RC, et al. Relation between age and clearance rate of nine investigational anticancer drugs from phase I pharmacokinetic data. Cancer Chemother Pharmacol 1994; 33: 493–6

    Article  PubMed  CAS  Google Scholar 

  45. Moscow JA, Schneider E, Cowan KH. Multidrug resistance. In: Pinedo HM, Longo DL, Chabner BA, editors. Cancer chemotherapy and biological response modifiers. Annual 16. Amsterdam: Elsevier Science BV, 1996: 111–31

    Google Scholar 

  46. Willman CL. Immunophenotyping and cytogenetics in older adults with acute myeloid leukemia: significance of expression of the multidrug resistance gene-1 (MDR1). Leukemia 1996; 10Suppl. 1: S33–5

    PubMed  Google Scholar 

  47. Rockwell O, Hughes CS, Kennedy KA. Effect of host age on microenvironmental heterogeneity and efficacy of combined modality therapy in solid tumors. Int J Rad Oncol Biol Phys 1991; 20: 259–63

    Article  CAS  Google Scholar 

  48. Reed JC. BCL-2: prevention of apoptosis as a mechanism of drug resistance. Hematol/Oncol Clin North Am 1995; 9: 450–73

    Google Scholar 

  49. Dixon DO, Neilan B, Jones SE, et al. Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience. J Clin Oncol 1986; 4: 295–305

    PubMed  CAS  Google Scholar 

  50. Peterson BA, Pajak TF, Cooper MR, et al. Effect of age on therapeutic response and survival in advanced Hodgkin’s disease. Cancer Treat Rep 1982; 66: 889–98

    PubMed  CAS  Google Scholar 

  51. Gelman RS, Taylor SG. Cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in women more than 65 years old with advanced breast cancer: the elimination of age trends in toxicity by using doses based on creatinine clearance. J Clin Oncol 1984; 2: 1404–13

    PubMed  CAS  Google Scholar 

  52. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989; 7: 1748–56

    PubMed  CAS  Google Scholar 

  53. Chantier C, Garnett ES, Parsons V, et al. Glomerular filtration rate measurement in man by the single injection of methods using 51Cr-EDTA. Clin Sci 1969; 37(1): 169–80

    Google Scholar 

  54. Daugaard G, Rossing N, Rorth M. Effects of cisplatin on different measures of glomerular function in the human kidney with special emphasis on high dose. Cancer Chemother Pharmacol 1988; 23: 163–7

    Google Scholar 

  55. Shank Jr WA, Balducci L. Recombinant hemopoietic growth factors: comparative hemopoietic response in younger and older subjects. J Am Geriatr Soc 1992; 40: 151–4

    PubMed  Google Scholar 

  56. Chatta GS, Price TH, Allen RC, et al. Effects of in vivo recombinant methionyl human granulocyte colony-stimulating factor on the neutrophil response and peripheral blood colony-forming cells in healthy young and elderly adult volunteers. Blood 1994; 84: 2923–9

    PubMed  CAS  Google Scholar 

  57. Vose JM. Cytokine use in the older patient. Semin Oncol 1995; 22 (1 Suppl. 1): 6–8

    PubMed  CAS  Google Scholar 

  58. Petrelli N, Douglass Jr HO, Herrera L, et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group. J Clin Oncol 1989; 7: 1419–26 [published erratum appears in J Clin Oncol 1990 Jan; 8 (1): 185]

    PubMed  CAS  Google Scholar 

  59. Stein BN, Petrelli NJ, Douglass HO, et al. Age and sex are independent predictors of 5-fluorouracil toxicity: analysis of a large scale phase III trial. Cancer 1995; 75: 11–7

    Article  PubMed  CAS  Google Scholar 

  60. Balducci L, Mowry K. Pharmacology and organ toxicity of chemotherapy in older patients. Oncology 1992; 6: 62–8

    PubMed  CAS  Google Scholar 

  61. Dresdale A, Bonow RO, Wesley R, et al. Prospective evaluation of doxorubicin-induced cardiomyopathy resulting from post-surgical adjuvant treatment of patients with soft tissue sarcomas. Cancer 1983; 52: 51–60

    Article  PubMed  CAS  Google Scholar 

  62. Palmeri ST, Bonow RO, Myers CE, et al. Prospective evaluation of doxorubicin cardiotoxicity by rest and exercise radionuclide angiography. Am J Cardiol 1986; 58: 607–13

    Article  PubMed  CAS  Google Scholar 

  63. Hortobagyi GN, Frye D, Buzdar AU, et al. Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma. Cancer 1989; 63: 37–45

    Article  PubMed  CAS  Google Scholar 

  64. Olson RD, Mushlin PS. Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J 1990; 4: 3076–86

    PubMed  CAS  Google Scholar 

  65. Speyer JL, Green MD, Kramer E, et al. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med 1988; 319: 745–52

    Article  PubMed  CAS  Google Scholar 

  66. Hochster H, Wasserheit C, Speyer J. Cardiotoxicity and cardioprotection during chemotherapy. Curr Opin Oncol 1995; 7: 304–9

    Article  PubMed  CAS  Google Scholar 

  67. Henderson IC, Allegra JC, Woodcock T, et al. Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J Clin Oncol 1989; 7: 560–71

    PubMed  CAS  Google Scholar 

  68. Fountzilas G, Afthonidis D, Geleris P, et al. Cardiotoxicity evaluation in patients treated with a mitoxantrone combination as adjuvant chemotherapy for breast cancer. Anticancer Res 1992; 12: 231–4

    PubMed  CAS  Google Scholar 

  69. Bennett JM, Muss HB, Doroshow JH, et al. A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma. J Clin Oncol 1988; 6: 1611–20

    PubMed  CAS  Google Scholar 

  70. Bennett JM, Byrne P, Desai A, et al. A randomized multicenter trial of cyclophosphamide, Novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer. Invest New Drugs 1985; 3: 179–85

    Article  PubMed  CAS  Google Scholar 

  71. Pouillart P, Follezou JY, Palangie T, et al. Long-term results of a randomised trial comparing regimens of cyclophosphamide and fluorouracil with either mitoxantrone or doxorubicin in patients with advanced breast cancer. Eur J Cancer 1994; 30A: 715–6

    PubMed  CAS  Google Scholar 

  72. Dunn CJ, Goa KL. Mitoxantrone: a review of its pharmacological properties and use in acute nonlymphoblastic leukaemia. Drugs Aging 1996; 9(2): 122–47

    Article  PubMed  CAS  Google Scholar 

  73. Mosseri M, Fingert HJ, Varticovski L, et al. In vitro evidence that myocardial ischemia resulting from 5-fluorouracil chemotherapy is due to protein kinase C-mediated vasoconstriction of vascular smooth muscle. Cancer Res 1993; 53: 3028–33

    PubMed  CAS  Google Scholar 

  74. Labianca R, Beretta G, Clerici M, et al. Cardiac toxicity of 5-fluorouracil: a study on 1083 patients. Tumori 1982; 68: 505–10

    PubMed  CAS  Google Scholar 

  75. Rezkalla S, Kloner RA, Ensley J, et al. Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective study. J Clin Oncol 1989; 7: 509–14

    PubMed  CAS  Google Scholar 

  76. Collins C, Weiden PL. Cardiotoxicity of 5-fluorouracil. Cancer Treat Rep 1987; 71: 733–6

    PubMed  CAS  Google Scholar 

  77. Ensley JF, Patel B, Kloner R, et al. The clinical syndrome of 5-fluorouracil cardiotoxicity. Invest New Drugs 1989; 7: 101–9

    Article  PubMed  CAS  Google Scholar 

  78. Haas CD, Coltman CA, Gottlieb JA, et al. Phase II evaluation of bleomycin: a Southwest Oncology Group study. Cancer 1976; 38: 8–12

    Article  PubMed  CAS  Google Scholar 

  79. Crooke ST, Comis RL, Einhorn LH, et al. Effects of variations in renal function on the clinical pharmacology of bleomycin administered as an iv bolus. Cancer Treat Rep 1977; 61: 1631–6

    PubMed  CAS  Google Scholar 

  80. Hrushesky WJ, Shimp W, Kennedy BJ. Lack of age-dependent cisplatin nephrotoxicity. Am J Med 1984; 76: 579–84

    Article  PubMed  CAS  Google Scholar 

  81. Sella A, Logothetis CJ, Dexeus FH, et al. Cisplatin combination chemotherapy for elderly patients with urothelial tumours. Br J Urol 1991; 67: 603–7

    Article  PubMed  CAS  Google Scholar 

  82. Raghavan D, Grundy R, Greenaway TM, et al. Pre-emptive (neoadjuvant) chemotherapy prior to radical radiotherapy for fit septuagenarians with bladder cancer: age itself is not a contra-indication. Br J Urol 1988; 62(2): 154–9

    Article  PubMed  CAS  Google Scholar 

  83. Lichtman SM, Buchholtz M, Marino J, et al. Use of cisplatin for elderly patients. Age Ageing 1992; 21: 202–4

    Article  PubMed  CAS  Google Scholar 

  84. Thyss A, Saudes L, Otto J, et al. Renal tolerance of cisplatin in patients more than 80 years old. J Clin Oncol 1994; 12: 2121–5

    PubMed  CAS  Google Scholar 

  85. Capizzi RL. Protection of normal tissues from the cytotoxic effects of chemotherapy by amifostine (Ethyol): clinical experiences. Semin Oncol 1994; 21Suppl. 11: 8–15

    PubMed  CAS  Google Scholar 

  86. van der Vijgh WJF, Peters GJ. Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by amifostine (ethyol): preclinical aspects. Semin Oncol 1994; 21Suppl. 11: 2–7

    PubMed  Google Scholar 

  87. Glick J, Rose P, Lurain J, et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 1996; 14: 2101–12

    PubMed  Google Scholar 

  88. Gottlieb D, Bradstock K, Koutts J, et al. The neurotoxicity of high-dose cytosine arabinoside is age-related. Cancer 1987; 60: 1439–41

    Article  PubMed  CAS  Google Scholar 

  89. Damon LE, Mass R, Linker CA. The association between high-dose cytarabine neurotoxicity and renal insufficiency. J Clin Oncol 1989; 7: 1563–8

    PubMed  CAS  Google Scholar 

  90. Rosenthal SM, Kaufman S. Vincristine neurotoxicity. Ann Intern Med 1974; 80: 733–7

    PubMed  CAS  Google Scholar 

  91. Jackson DV, Wells HB, Atkins JN, et al. Amelioration of vincristine neurotoxicity by glutamic acid. Am J Med 1988; 84: 1016–22

    Article  PubMed  CAS  Google Scholar 

  92. Mouridsen HT, Jacobsen E. Pharmacokinetics of cyclophosphamide in renal failure. Acta Pharmacol Toxicol 1975; 36: 409–14

    Article  CAS  Google Scholar 

  93. Juma FD, Rogers HJ, Trounce JR. Effect of renal insufficiency on the pharmacokinetics of cyclophosphamide and some of its metabolites. Eur J Clin Pharmacol 1981; 19: 443–51

    Article  PubMed  CAS  Google Scholar 

  94. Kristensen LO, Weismann K, Hutters L. Renal function and the rate of disappearance of methotrexate from serum. Eur J Clin Pharmacol 1975; 8: 439–44

    Article  PubMed  CAS  Google Scholar 

  95. Cadman EC, Lundberg WB, Bertino JR. Systemic methotrexate toxicity: a pharmacological study of its occurrence after intrathecal administration in a patient with renal failure. Arch Intern Med 1976; 136: 1321–2

    Article  PubMed  CAS  Google Scholar 

  96. Milano G, Etienne MC, Cassuto-Vigurier E. Influence of age and sex on fluorouracil clearance. J Clin Oncol 1992; 10: 1171–5

    PubMed  CAS  Google Scholar 

  97. McLeod BF, Lawrence HJ, Smith DW, et al. Fatal bleomycin toxicity from a low cumulative dose in a patient with renal insufficiency. Cancer 1987; 60: 2617–20

    Article  PubMed  CAS  Google Scholar 

  98. Fleming RA, Miller AA, Stewart CF. Etoposide: an update. Clin Pharm 1989; 8: 274–93

    PubMed  CAS  Google Scholar 

  99. Stewart CF. Use of etoposide in patients with organ dysfunction: pharmacokinetic and pharmacodynamic considerations. Cancer Chemother Pharmacol 1994; 34: 576–83

    Article  Google Scholar 

  100. Bennett WM, Aronoff GR, Morrison G, et al. Drug prescribing in renal failure: dosing guidelines for adults. Am J Kid Dis 1983; 3: 155–80

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Comprehensive Cancer Center of Wake Forest University, Medical Center Boulevard, Winston-Salem, North Carolina, 27157, USA

    Gretchen G. Kimmick, Ronald Fleming & Hyman B. Muss

  2. H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, Florida, USA

    Lodovico Balducci

Authors
  1. Gretchen G. Kimmick
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ronald Fleming
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hyman B. Muss
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lodovico Balducci
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kimmick, G.G., Fleming, R., Muss, H.B. et al. Cancer Chemotherapy in Older Adults. Drugs & Aging 10, 34–49 (1997). https://doi.org/10.2165/00002512-199710010-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-199710010-00004

Keywords

Search

Navigation